• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Tandem Diabetes Care Inc.

    5/29/25 4:42:26 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email
    SD 1 a2025formsd.htm SD Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________________
    FORM SD
    Specialized Disclosure Report
    ___________________________
    Tandem Diabetes Care, Inc.
    (Exact name of registrant as specified in its charter)
    _________

    Delaware001-3618920-4327508
    (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    12400 High Bluff Drive, San Diego, CA92130
    (Address of principal executive offices)(Zip Code)


    Shannon M. Hansen
    Tandem Diabetes Care, Inc.
    Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
    (858) 366-6900
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    ____________________________
    Check the appropriate box below to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    ☒    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period January 1 to December 31, 2024.
    ____________________________
    1


    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Tandem Diabetes Care, Inc. (“Tandem”) is filing a Conflict Minerals Report for the reporting period January 1 to December 31, 2024 as an exhibit to this specialized disclosure report on Form SD (“Form SD”) and is providing that report on Tandem’s website at http://investor.tandemdiabetes.com/corporate-governance/esg.

    Item 1.02 Exhibit

    The Conflict Minerals Report required by Item 1.01 is filed as an exhibit to this Form SD.

    Section 2 - Exhibits

    Item 2.01 Exhibits

    The following exhibit is filed as part of this Form SD:

    NumberDescription
    1.01
    Tandem Diabetes Care, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2024.

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Tandem Diabetes Care, Inc.
    By:
    /s/ Shannon M. Hansen
    Shannon M. Hansen
    Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary

    Date: May 29, 2025
    3
    Get the next $TNDM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    6/16/2025$24.00Hold
    Truist
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    3/4/2025$35.00 → $24.00Buy → Neutral
    Citigroup
    3/3/2025$38.00 → $22.00Overweight → Equal Weight
    Wells Fargo
    2/28/2025$35.00 → $25.00Outperform → Mkt Perform
    Bernstein
    12/2/2024$45.00Equal-Weight → Overweight
    Morgan Stanley
    11/6/2024$42.00Outperform
    Bernstein
    More analyst ratings

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 207 shares, increasing direct ownership by 0.95% to 21,219 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:32 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,414 shares and covered exercise/tax liability with 3,846 shares, increasing direct ownership by 14% to 28,763 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:21 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Director Cha Myoungil converted options into 1,749 shares, increasing direct ownership by 15% to 13,699 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:10 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David bought $12,364 worth of shares (532 units at $23.24) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/19/24 5:23:14 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Allen Dick bought $94,778 worth of shares (5,000 units at $18.96), increasing direct ownership by 33% to 19,962 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/29/23 4:10:39 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    SEC Filings

    See more
    • SEC Form SD filed by Tandem Diabetes Care Inc.

      SD - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/29/25 4:42:26 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/23/25 4:21:45 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Other Events

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/12/25 5:16:49 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

      Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their

      6/20/25 8:30:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott's future glucose-ketone sensor has the potential to help

      6/10/25 8:30:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Upcoming Conference Presentations

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00am Eastern Time (7:00am Pacific Time), Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 3:45pm Eastern Time (12:45pm Pacific Time), and Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40am Eastern Time (5:40am Pacific Time). The presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live w

      5/6/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 28, 2025 - FDA Roundup: February 28, 2025

      For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

      2/28/25 5:00:47 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • November 7, 2023 - FDA Roundup: November 7, 2023

      For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

      11/7/23 3:38:18 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care